Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

Sponsor
AstraZeneca
Study ID
NCT06727227
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • trastuzumab deruxtecan — DRUG
    T-DXd

Study Details

A longitudinal, non-interventional study with trastuzumab deruxtecan for patients with HER2-low expressing unresectable or metastatic breast cancer in Bulgaria and Slovenia

Key Dates

Start date
Jan 29, 2025
Status verified
Jun 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
135 participants (estimated)

Primary Outcome Measure

Real-world Time to Next Treatment (rwTTNT1, median, 95% CI, measured in months) [ Time Frame: Baseline up to 19 months ]

Central Contacts

  • AstraZeneca Clinical Study Information Center, Study Information Center
    1-877-240-9479
    [email protected]

Related Studies